Skip to main content
TipRanks
Go Ultimate75% OFF

Caribou Biosciences (CRBU) Drug Pipeline

1,002 Followers
Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Cb-010Lupus Nephritis, Systemic Lupus Erythematosus, Lupus Erythematosus, LupusPhase IWithdrawnCRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)Dec 18, 2024―
Cb-012Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, In RelapsePhase ITerminatedCRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid LeukemiaNov 06, 2023―
Cb-011Relapsed/Refractory Multiple MyelomaPhase IRecruitingCRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple MyelomaDec 19, 2022―
Cyclophosphamide, Fludarabine, Cb-010Lymphoma, Non Hodgkin Lymphoma, Lymphoma, Non-Hodgkin, B Cell Lymphoma, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, B Cell Non-Hodgkin's LymphomaPhase IRecruitingCRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)Nov 16, 2020―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Caribou Biosciences, Inc. (CRBU) have in its pipeline
Caribou Biosciences CRBU is currently developing the following drugs: Cb-010, Cb-012, Cb-011, Cyclophosphamide, Fludarabine, Cb-010. These drug candidates are in various stages of clinical development as the company works toward FDA approval.